Clinical Report: Diverse Orthobiologics in Musculoskeletal Disorders

Overview

This scoping review examines the biological heterogeneity of orthobiologics, including PRP, cytokine-enriched serum, and extracellular vesicles.

Background

Orthobiologics, particularly autologous blood-derived products like platelet-rich plasma (PRP), are widely used in musculoskeletal medicine. However, the variability in their composition and mechanisms can lead to confusion and inconsistent clinical applications. Understanding these differences is crucial.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

• PRP primarily functions through the release of growth factors for tissue repair.
• Formulations with leukocytes and monocytes focus on immune modulation and inflammatory pathways.
• Acellular cytokine-rich serum provides immunomodulatory effects via soluble mediators like IL-1Ra.
• Extracellular vesicles (EVs) are experimental with unclear clinical efficacy as paracrine modulators.
• The only triple-blind trial of exosomes in knee osteoarthritis confirmed safety but showed no superiority over placebo.

Clinical Implications

Clinicians should be aware of the distinct biological mechanisms of various orthobiologics.

Conclusion

The review emphasizes the importance of understanding the biological diversity among orthobiologics.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Knee Surgery, Sports Traumatology, Arthroscopy, 2013 -- Intra-Articular Applications of Platelet-Rich Plasma: A Comprehensive Review of Preclinical and Clinical Evidence for Joint Degeneration Management
3. Knee Surgery, Sports Traumatology, Arthroscopy, 2023 -- Impact of Cell-Based Treatments on Osteoarthritis Progression in Animal Studies: A Systematic Review by the ESSKA Orthobiologic Initiative. Part 2: Injectable Therapies Utilizing Bone Marrow-Derived Cells
4. Management of Osteoarthritis of the Knee (Non-Arthroplasty), AAOS, 2021
5. AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis, 2026
6. The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA‐ORBIT consensus. Part 1—Blood‐derived products, 2024
7. Minimal information for studies of extracellular vesicles (MISEV2023)
8. Knee Surgery, Sports Traumatology, Arthroscopy — Impact of Two Distinct Platelet-Rich Plasma Formulations on Synoviocyte Behavior
9. Management of Osteoarthritis of the Knee (Non-Arthroplasty)
10. AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis
11. The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA‐ORBIT consensus. Part 1—Blood‐derived products (platelet‐rich plasma) - Laver - 2024 - Knee Surgery, Sports Traumatology, Arthroscopy - Wiley Online Library
12. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
13. Effect of Intra-articular Platelet-Rich Plasma vs Placebo on Pain and Cartilage Volume in Knee Osteoarthritis
14. The effect of intra-articular autologous protein solution on knee osteoarthritis symptoms - PubMed
15. Safety and efficacy of placental mesenchymal stromal cells-derived extracellular vesicles in knee osteoarthritis: a randomized, triple-blind, placebo-controlled clinical trial - PMC